Spruzit Neu (frilandsgrønsager)

Primær information

  • Handelsnavn:
  • Spruzit Neu (frilandsgrønsager) Emulsionskoncentrat
  • Lægemiddelform:
  • Emulsionskoncentrat
  • Sammensætning:
  • 4,59 g/l pyrethrin I og II; 825 g/l rapsolie
  • Brugt til:
  • Planter
  • Medicin typen:
  • agrokemiske

Dokumenter

  • for sundhedspersonale:
  • Oplysningerne indlægssedlen for dette produkt er i øjeblikket ikke tilgængelig, kan du sende en anmodning til vores kundeservice, og vi vil give dig besked, så snart vi er i stand til at opnå det.


    Anmode informationsbrochure for sundhedspersonale.

Lokation

  • Fås i:
  • Spruzit Neu (frilandsgrønsager) Emulsionskoncentrat
    Danmark
  • Sprog:
  • dansk

Andre oplysninger

Status

  • Kilde:
  • SEGES Landbrug & Fødevarer
  • Autorisation status:
  • Udgået
  • Autorisationsnummer:
  • Må ikke anvendes nærmere end 30 meter fra vandmiljøet (vandløb, søer m.v.) for at beskytte organismer, der lever i vand.
  • Sidste ændring:
  • 23-07-2018

Indlægsseddel

Spruzit Neu – Insektmiddel

(frilandsgrønsager)

Spruzit Neu – Insektmiddel, må kun anvendes til bekæmpelse af insekter i

økologiske frilandsgrønsager

“ADVARSEL

For at nedsætte risikoen for mennesker og miljø skal brugsanvis-

ningen følges nøje. Meget giftig for organismer, der lever i vand;

kan forårsage uønskede langtidsvirkninger i vandmiljøet (R50/53).

Vær opmærksom på, at Arbejdstilsynet har regler for arbejde med

og udsættelse for plantebeskyttelsesmidler. Læs nærmere i det

eventuelt lovpligtige sikkerhedsdatablad samt i Arbejdstilsynets

informationsmateriale om bekæmpelsesmidler. Vask huden efter

arbejdet. Anvendelse og opbevaring sker alene efter dispensation

fra godkendelsesordningen for pesticider. Dispensation til anven-

delse gælder i perioden: 1. juni – 28. september 2014. Tilladelse til

opbevaring bortfalder den 28. september 2014.

Overtrædelse af nedenstående særligt fremhævede forskrifter

kan medføre straf: Må kun anvendes til bekæmpelse af insekter i

økologiske frilandsgrønsager. Må ikke anvendes mod andre ska-

devoldere og ikke i højere doseringer end de i brugsanvisningen

nævnte. Må højst behandles 2 gange indenfor samme vækstsæ-

son med mindst 7 dages interval og ikke senere end 3 dage før

høst. Må ikke anvendes nærmere end 30 meter fra vandmiljøet

(vandløb, søer mv.) for at beskytte organismer, der lever i vand.

Undgå forurening af vandmiljøet med produktet eller med

beholdere, der har indeholdt produktet. Rens ikke sprøjteudstyr

nær overfladevand.

Opbevares utilgængeligt for børn.

Må ikke opbevares sammen med fødevarer, drikkevarer og

foderstoffer.

Brugsanvisning:

Spruzit NEU er et lysnedbrydeligt pyretrumpro-

dukt udvundet af Chysanthemum, der virker som

kontaktgift over for specielt gnavende og sugende

insekter.

Midlet

påvirker

insekternes

nervesy-

stem og øjeblikkeligt standses indtagelse af føde

samt evnen til at formere sig. Skadevolderne dør

i løbet af få timer.

Sprøjtetidspunkt:

Ved forventet klækning af æg og/eller konstateret

allerførste angreb af skadevolder, eller ved over-

skridelse af officielle skadetærskler. Behandlingen

udføres

uden

biers

flyvetid

(kl.

21-03,

dansk

sommertid) eller senest i de tidligste morgentimer.

Sprøjt aldrig i direkte sollys eller ved temperaturer

under 5⁰C eller over 20⁰C.

Sprøjteteknik:

Spruzit NEU er et kontaktmiddel, hvorfor en god

fordeling i afgrøden er en forudsætning for ef-

fektiv bekæmpelse af skadevolderen. Der anven-

des ca. 800-1200 l sprøjtevæske pr. ha. Det er

vigtigt at mængden af udbragt sprøjtevæske per

ha. tilpasses således, at alle plantedele dækkes

grundigt, men væsken ikke drypper fra kulturen.

Størst vandmængde i tætte og bladrige afgrøder.

Rens sprøjten grundigt efter behandling.

Blandinger:

Spruzit NEU bør ikke blandes med andre produk-

ter. Færdig sprøjtevæske skal anvendes samme

dag.

Tålsomhed:

Generelt

ingen

problemer

tålsomhed

Spruzit

NEU,

gennemfør

altid

tålsom-

hedsafprøvning (vent i en uge) på en mindre del

af kulturen inden hver anvendelse i erhvervskul-

turer. Især hurtigt voksende afgrøder med tyndt

vokslag kan være udsatte.

Praktiske oplysninger:

Rester skal afleveres til den kommunale affalds-

ordning for farligt affald. Tomme beholdere kan

bortskaffes med dagrenovationen. Den tomme

beholder bør skylles inden bortskaffelse. Skyl-

levandet hældes op i sprøjtevæsken.

Deklaration: Insektmiddel registreringsnummer 364-64. Omfattet

af Miljøstyrelsens dispensation af maj 2014. Indhold: 4,59 g/l py-

rethrin I + II (0,5%) udvundet af Chrysanthemum cinerariaefolium

og 825,3 g/l rapsolie (83%). Denne emballage indeholder 10 liter.

”Midlet er et emulsionskoncentrat.” Midlet er holdbart 5 år efter

produktionsdatoen anført på emballagen. Batchnummer er også

påført emballagen. Indehaveren af denne dispensation er Grøn

plantebeskyttelse Aps og ECOstyle A/S distribuerer varen for Grøn

Plantebeskyttelse Aps.

Førstehjælp: Kommer midlet i

øjnene skylles straks grundigt

med vand og læge kontaktes.

Kommer midlet på huden vaskes

straks med store mængder vand.

Indhold 10 liter koncentrat

Distributør:

ECOstyle A/S, Hvidkærvej 17,

5250 Odense SV, Tlf. 70 22 70 67

Godkendelsesindehaver:

W. Neudorff GmbH KG, An der Mühle 3

D-31860 Emmerthal, Tyskland

Varenr.: 1072 / Reg.nr. 364-64

 

Kultur

Skadegører

Dosering

Vand pr. ha

Sprøjte-

frist

Salat

Sommerfuglelarver,

bladlus og trips

6 l/ha. Maksimalt 2 behandlinger med

7 dages interval

800-1200 l

3 dage

Hovedkål, bladkål og

blomsterkål

Sommerfuglelarver,

kålbladlus, trips og

glimmerbøsser

6 l/ha. Maksimalt 2 behandlinger med

7 dages interval

800-1200 l

3 dage

Gulerod, persillerod,

pastinak og selleri

Sugende insekter bl.a.

bladlus

6 l/ha. Maksimalt 2 behandlinger med

7 dages interval

800 l

3 dage

Porre

Trips

6 l/ha. Maksimalt 2 behandlinger med

7 dages interval

800-1200 l

3 dage

Løg

Bladlus og trips

6 l/ha. Maksimalt 2 behandlinger med

7 dages interval

800 l

3 dage

Miljøfarlig

14-6-2010

Change of the reimbursement for certain cardiovascular products as of 15 November 2010

Change of the reimbursement for certain cardiovascular products as of 15 November 2010

The Reimbursement Committee and the Danish Medicines Agency have reviewed some of the medicinal products used for the treatment of cardiovascular disease (antihypertensives) in order to assess whether they meet the criteria for public reimbursement. The medicinal products concerned are the so-called angiotensin II antagonists and renin inhibitors.

Danish Medicines Agency

3-6-2010

Consultation responses on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicinal products in ATC groups C09C, C09D and C09X (angiotensin II antagonists and renin inhibitors)

Consultation responses on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicinal products in ATC groups C09C, C09D and C09X (angiotensin II antagonists and renin inhibitors)

The Reimbursement Committee’s recommendation concerning the future reimbursement status of medicinal products in ATC groups C09C, C09D and C09X (angiotensin II antagonists and renin inhibitors) was open for consultation until 7 May 2010.

Danish Medicines Agency

21-4-2010

Decision on future reimbursement status of losartan-containing medicines (C09CA01 and C09DA01) - angiotensin II antagonists

Decision on future reimbursement status of losartan-containing medicines (C09CA01 and C09DA01) - angiotensin II antagonists

On 16 April 2010, the Danish Medicines Agency decided on the future reimbursement status of some of the losartan-containing medicines in ATC groups C09C and C09D, making these products eligible for general reimbursement as of 19 April 2010.

Danish Medicines Agency

31-3-2010

Consultation on the Reimbursement Committee's recommendation concerning the reimbursement status of medicinal products in ATC groups C09C, C09D and C09X (angiotensin II antagonists and renin inhibitors)

Consultation on the Reimbursement Committee's recommendation concerning the reimbursement status of medicinal products in ATC groups C09C, C09D and C09X (angiotensin II antagonists and renin inhibitors)

At the Danish Medicines Agency's request, the Reimbursement Committee has reassessed the reimbursement status of medicinal products in ATC groups C09C, C09D and C09X (angiotensin II antagonists and renin inhibitors).

Danish Medicines Agency

24-3-2010

The Danish Medicines Agency begins ad hoc reassessment of reimbursement status of medicines in ATC groups C09C, C09D and C09X

The Danish Medicines Agency begins ad hoc reassessment of reimbursement status of medicines in ATC groups C09C, C09D and C09X

On 8 March 2010, a number of pharmaceutical companies put generic copies of the angiotensin II antagonist losartan on the market at prices comparable to those of the cheapest ACE inhibitors.

Danish Medicines Agency

8-9-2008

Reassessment of reimbursement status of medicinal products for cardiovascular diseases – additional recommendation from the Reimbursement Committee

Reassessment of reimbursement status of medicinal products for cardiovascular diseases – additional recommendation from the Reimbursement Committee

The Danish Medicines Agency has asked the Reimbursement Committee to reassess the reimbursement status of medicinal products authorised for marketing in Denmark in the ATC groups C02 (antihypertensives), C03 (diuretics), C07 (beta blocking agents), C08 (calcium channel blockers) and C09 (ACE inhibitors, angiotensin II antagonists and renin inhibitors).

Danish Medicines Agency

14-2-2008

Reassessment of reimbursement status for medicinal products for the treatment of cardiovascular diseases

Reassessment of reimbursement status for medicinal products for the treatment of cardiovascular diseases

Following a request from the Danish Medicines Agency, the Reimbursement Committee has reassessed the reimbursement status for medicinal products authorised for marketing in Denmark in ATC groups C02 (antihypertensives), C03 (diuretics), C07 (beta blocking agents), C08 (calcium channel blockers) and C09 (ACE inhibitors, angiotensin II antagonists and renin inhibitors).

Danish Medicines Agency

9-7-2018

Pexion (Boehringer Ingelheim Vetmedica GmbH)

Pexion (Boehringer Ingelheim Vetmedica GmbH)

Pexion (Active substance: Imepitoin) - Centralised - 2-Monthly update - Commission Decision (2018)4433 of Mon, 09 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/2543/II/11/G

Europe -DG Health and Food Safety

4-7-2018

Tecentriq (Roche Registration GmbH)

Tecentriq (Roche Registration GmbH)

Tecentriq (Active substance: atezolizumab) - Centralised - 2-Monthly update - Commission Decision (2018)4336 of Wed, 04 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4143/II/10

Europe -DG Health and Food Safety

4-7-2018

Simponi (Janssen Biologics B.V.)

Simponi (Janssen Biologics B.V.)

Simponi (Active substance: golimumab) - Centralised - 2-Monthly update - Commission Decision (2018) 4350 of Wed, 04 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/992/II/79

Europe -DG Health and Food Safety

3-7-2018

Samsca (Otsuka Pharmaceutical Europe Ltd)

Samsca (Otsuka Pharmaceutical Europe Ltd)

Samsca (Active substance: tolvaptan) - Centralised - 2-Monthly update - Commission Decision (2018) 4250 of Tue, 03 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/980/II/31

Europe -DG Health and Food Safety

3-7-2018

Jinarc (Otsuka Pharmaceutical Europe Ltd)

Jinarc (Otsuka Pharmaceutical Europe Ltd)

Jinarc (Active substance: tolvaptan) - Centralised - 2-Monthly update - Commission Decision (2018)4243 of Tue, 03 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2788/II/16

Europe -DG Health and Food Safety

29-6-2018

Porcilis PCV M Hyo (Intervet International B.V.)

Porcilis PCV M Hyo (Intervet International B.V.)

Porcilis PCV M Hyo (Active substance: Porcine circovirus and Mycoplasma hyopneumoniae vaccine (inactivated)) - Centralised - 2-Monthly update - Commission Decision (2018)4166 of Fri, 29 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/3796/II/7

Europe -DG Health and Food Safety

20-6-2018

Blincyto (Amgen Europe B.V.)

Blincyto (Amgen Europe B.V.)

Blincyto (Active substance: blinatumomab) - Centralised - Authorisation - Switch to non-conditional - Commission Decision (2018)3953 of Wed, 20 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/3731/II/9

Europe -DG Health and Food Safety

11-6-2018

Cimzia (UCB Pharma S.A.)

Cimzia (UCB Pharma S.A.)

Cimzia (Active substance: certolizumab pegol ) - Centralised - 2-Monthly update - Commission Decision (2018)3768 of Mon, 11 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/1037/II/65

Europe -DG Health and Food Safety

11-6-2018

Cerdelga (Genzyme Europe B.V.)

Cerdelga (Genzyme Europe B.V.)

Cerdelga (Active substance: eliglustat) - Centralised - 2-Monthly update - Commission Decision (2018)3754 of Mon, 11 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/3724/II/15/G

Europe -DG Health and Food Safety

11-6-2018

TAGRISSO (AstraZeneca AB)

TAGRISSO (AstraZeneca AB)

TAGRISSO (Active substance: osimertinib) - Centralised - 2-Monthly update - Commission Decision (2018)3757 of Mon, 11 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4124/II/19

Europe -DG Health and Food Safety

11-6-2018

Pradaxa (Boehringer Ingelheim International GmbH)

Pradaxa (Boehringer Ingelheim International GmbH)

Pradaxa (Active substance: dabigatran etexilate mesilate) - Centralised - 2-Monthly update - Commission Decision (2018)3755 of Mon, 11 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/829/II/108

Europe -DG Health and Food Safety

11-6-2018

Xultophy (Novo Nordisk A/S)

Xultophy (Novo Nordisk A/S)

Xultophy (Active substance: insulin degludec / liraglutide) - Centralised - 2-Monthly update - Commission Decision (2018)3779 of Mon, 11 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2647/II/23

Europe -DG Health and Food Safety

11-6-2018

Bexsero (GlaxoSmithKline Vaccines S.r.l.)

Bexsero (GlaxoSmithKline Vaccines S.r.l.)

Bexsero (Active substance: Meningococcal group B Vaccine (rDNA, component, adsorbed)) - Centralised - 2-Monthly update - Commission Decision (2018)3769 of Mon, 11 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2333/II/59

Europe -DG Health and Food Safety

6-6-2018

Prolia (Amgen Europe B.V.)

Prolia (Amgen Europe B.V.)

Prolia (Active substance: denosumab) - Centralised - 2-Monthly update - Commission Decision (2018) 3685 of Wed, 06 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/1120/II/68

Europe -DG Health and Food Safety

4-6-2018

Yervoy (Bristol-Myers Squibb Pharma EEIG)

Yervoy (Bristol-Myers Squibb Pharma EEIG)

Yervoy (Active substance: ipilimumab) - Centralised - 2-Monthly update - Commission Decision (2018)3618 of Mon, 04 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2213/II/55

Europe -DG Health and Food Safety

4-6-2018

Eliquis (Bristol-Myers Squibb/Pfizer EEIG)

Eliquis (Bristol-Myers Squibb/Pfizer EEIG)

Eliquis (Active substance: apixaban) - Centralised - 2-Monthly update - Commission Decision (2018)3616 of Mon, 04 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2148/II/50

Europe -DG Health and Food Safety

4-6-2018

Alecensa (Roche Registration GmbH)

Alecensa (Roche Registration GmbH)

Alecensa (Active substance: alectinib) - Centralised - 2-Monthly update - Commission Decision (2018)3621 of Mon, 04 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4164/II/10

Europe -DG Health and Food Safety

15-5-2018

CABOMETYX (Ipsen Pharma)

CABOMETYX (Ipsen Pharma)

CABOMETYX (Active substance: cabozantinib) - Centralised - 2-Monthly update - Commission Decision (2018)3015 of Tue, 15 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4163/II/3

Europe -DG Health and Food Safety

15-5-2018

Repatha (Amgen Europe B.V.)

Repatha (Amgen Europe B.V.)

Repatha (Active substance: evolocumab) - Centralised - 2-Monthly update - Commission Decision (2018)3014 of Tue, 15 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/3766/II/17/G

Europe -DG Health and Food Safety

3-5-2018

Perjeta (Roche Registration GmbH)

Perjeta (Roche Registration GmbH)

Perjeta (Active substance: pertuzumab) - Centralised - 2-Monthly update - Commission Decision (2018)2771 of Thu, 03 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2547/II/35

Europe -DG Health and Food Safety

3-5-2018

Ivemend (Merck Sharp and Dohme Limited)

Ivemend (Merck Sharp and Dohme Limited)

Ivemend (Active substance: fosaprepitant) - Centralised - 2-Monthly update - Commission Decision (2018)2777 of Thu, 03 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/743/II/37

Europe -DG Health and Food Safety

5-3-2018

EU/3/16/1789 (La Jolla Pharmaceutical II BV)

EU/3/16/1789 (La Jolla Pharmaceutical II BV)

EU/3/16/1789 (Active substance: Synthetic human hepcidin) - Transfer of orphan designation - Commission Decision (2018)1427 of Mon, 05 Mar 2018 European Medicines Agency (EMA) procedure number: EMA/OD/144/16/T/02

Europe -DG Health and Food Safety

5-3-2018

EU/3/15/1555 (La Jolla Pharmaceutical II BV)

EU/3/15/1555 (La Jolla Pharmaceutical II BV)

EU/3/15/1555 (Active substance: Synthetic hepcidin) - Transfer of orphan designation - Commission Decision (2018)1426 of Mon, 05 Mar 2018 European Medicines Agency (EMA) procedure number: EMA/OD/092/15/T/02

Europe -DG Health and Food Safety